Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial

The Lancet Oncology 2026 Open access

Read full text
Authors: Linde van den Hoek, Mark C. Burgmans, T. M. L. Tong, Jelle J. Goeman, Frank Speetjens, Stephanie M. Zunder, Arian R. van Erkel, Rutger van der Meer, Carla S. P. van Rijswijk, Jacob Lutjeboer, Dominique Koolhaas, Mare Jonker-Bos
+9 more Inge C.F.M. Roozen, Sabine Kropff, Els van Persijn van Meerten, R. W. M. Zoethout, Elske Sitsen, Hendrik J. F. Helmerhorst, Fred G. J. Tijl, Christian Blank, Ellen Kapiteijn
DOI: 10.1016/s1470-2045(25)00720-x
Cited by: 4
References: 30

Fields of Study & Subjects

Ocular Oncology and Treatments Melanoma and MAPK Pathways Ocular Diseases and Behçet’s Syndrome

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
3
Pages
372–382
Publication date
1 March 2026
Language
EN